Who Makes Ozempic? The Manufacturer Explained

Who makes Ozempic? Novo Nordisk, a Danish pharmaceutical company headquartered in Denmark and long established in diabetes care and insulin. Novo Nordisk owns the brand, holds the approvals, sets the list price, runs the savings programs, and manufactures every legitimate Ozempic pen that reaches a pharmacy counter. That single fact turns out to explain a surprising amount about cost, supply, and the counterfeit products circulating online.

This guide covers the Ozempic manufacturer in practical terms: what else the company makes, how its lineup differs from Eli Lilly's, where production happens at a high level, and why the name on the pen matters when you are trying to get a real prescription filled at a real price.

Who makes Ozempic: Novo Nordisk explained

Novo Nordisk is a Danish pharmaceutical company with deep roots in metabolic medicine. Its historical business is insulin and diabetes care, which is the context that matters for understanding Ozempic. Semaglutide, the active ingredient in Ozempic, was developed as a treatment for type 2 diabetes. The weight-loss effect that made the brand a household name was a consequence of that diabetes work, not the starting point.

Ozempic itself is a once-weekly injection approved for type 2 diabetes. It is supplied in doses of 0.25 mg, 0.5 mg, 1 mg and 2 mg, with 2 mg as the maximum. The 0.25 mg step is a starting dose used to let the body adjust, not a maintenance dose. If you want the drug-level detail rather than the company-level view, the Ozempic overview and semaglutide explained go deeper into how the molecule works.

The Ozempic manufacturer's full GLP-1 lineup

People often assume Ozempic is a standalone product. It is not. It sits inside a family of Novo Nordisk medications that share ingredients and confuse shoppers constantly, because the same molecule appears under different brand names with different approved uses.

The semaglutide brands

• Ozempic: weekly injection, approved for type 2 diabetes, doses 0.25, 0.5, 1 and 2 mg, maximum 2 mg.
• Wegovy: weekly injection, approved for chronic weight management, with a five-step titration of 0.25, 0.5, 1, 1.7 and 2.4 mg, maximum 2.4 mg. See the Wegovy overview for the full picture.
• Rybelsus: a daily oral tablet, approved for type 2 diabetes only, in 3, 7 and 14 mg strengths. It is the same active ingredient in swallowable form.

All three are semaglutide. All three come from the same Ozempic manufacturer. The differences are the delivery format, the approved use and the ceiling dose. That is why a person can be told Ozempic is not covered for weight loss but Wegovy might be, even though the molecule is identical.

The liraglutide brands

Novo Nordisk also makes two older GLP-1 medications built on liraglutide rather than semaglutide: Saxenda, approved for weight management, and Victoza, approved for type 2 diabetes. They are daily injections rather than weekly ones, and they largely predate the current wave of interest. They remain part of the company's lineup and still appear on formularies.

Novo Nordisk versus Eli Lilly: two makers, two molecules

The other name that dominates this category is Eli Lilly, an American pharmaceutical company that makes the tirzepatide brands. Tirzepatide is a different molecule from semaglutide, and Eli Lilly has no involvement in Ozempic whatsoever. Mixing up the two makers is the single most common source of confusion in this space, so the table below maps maker to brand.

Maker	Brand	Active ingredient	Approved use
Novo Nordisk	Ozempic	Semaglutide	Type 2 diabetes (weekly injection, max 2 mg)
Novo Nordisk	Wegovy	Semaglutide	Chronic weight management (weekly injection, max 2.4 mg)
Novo Nordisk	Rybelsus	Semaglutide	Type 2 diabetes (daily oral tablet, 3/7/14 mg)
Novo Nordisk	Saxenda	Liraglutide	Weight management
Novo Nordisk	Victoza	Liraglutide	Type 2 diabetes
Eli Lilly	Mounjaro	Tirzepatide	Type 2 diabetes (approved May 2022)
Eli Lilly	Zepbound	Tirzepatide	Chronic weight management (approved November 2023)

Both tirzepatide brands are dosed weekly at 2.5, 5, 7.5, 10, 12.5 and 15 mg. Mounjaro and Zepbound are to Eli Lilly roughly what Ozempic and Wegovy are to Novo Nordisk: the same molecule, split across a diabetes brand and a weight brand. For a side-by-side of the two lead products, see Ozempic versus Mounjaro, and for the wider regulatory map, FDA-approved GLP-1 medications.

On effectiveness, the published trial figures differ. Semaglutide 2.4 mg produced about 14.9% mean body-weight loss over 68 weeks in the STEP-1 trial. Tirzepatide reached up to about 20.9% over 72 weeks in SURMOUNT-1. These are separate trials in different populations rather than a head-to-head comparison, so they indicate the general scale of effect rather than a definitive ranking, and individual results vary widely.

Where the Ozempic manufacturer produces the medication

Novo Nordisk operates production sites internationally, including in Denmark and the United States. Manufacturing a peptide medication like semaglutide, then filling and finishing it into prefilled injection pens, is a multi-stage process that can span more than one facility and more than one country before a pen is boxed and shipped. That is normal for modern pharmaceuticals and is not a quality concern in itself.

What matters for a patient is not the address of a plant but the integrity of the chain that runs from the maker to a licensed pharmacy. Product that travels that route is the manufacturer's product. Product that arrives any other way is not, whatever the box says.

Why knowing who makes Ozempic actually matters

Savings programs come from the maker

Manufacturer savings and cash-pay programs are run by the company that makes the drug, not by pharmacies or telehealth services. Novo Nordisk runs NovoCare; Eli Lilly runs LillyDirect. Approximate US figures put the Ozempic list price at about $997 per month and Wegovy at about $1,349, with a NovoCare cash option advertised at roughly $499. These numbers are approximate and they change, so verify current terms and eligibility directly before budgeting around them. The Ozempic savings card guide covers how these programs work in practice.

Supply is managed by the maker

When a GLP-1 medication is hard to find, the constraint sits with the manufacturer and its production and distribution capacity. Shortages have historically hit particular dose strengths rather than an entire brand at once, which is why a pharmacy may have one pen size and not another. Your prescriber and pharmacist track this far better than any website can.

The supply chain is your counterfeit defense

Because demand has outrun supply at times, a market in counterfeit and unapproved product has grown around these brands. The practical rule is simple: obtain medication only through a licensed US pharmacy with a valid prescription. Be wary of any seller offering Ozempic without a prescription, at an implausible price, from an overseas website, or through social media. A product that did not come from Novo Nordisk through the legitimate supply chain is not Ozempic, regardless of the label on the pen.

Compounded semaglutide is a separate category again, with its own legal and quality considerations, and it is not made by the Ozempic manufacturer. Compounded GLP-1 medications online covers what that distinction means.

This article is educational only and is not medical advice. It describes manufacturers, brands and approved uses; it does not recommend any medication or company. Prices and program terms are approximate and change frequently. Talk to a licensed clinician about whether any GLP-1 medication is appropriate for you, and obtain any prescription medication only through a licensed pharmacy.